Singular Health Group Ltd · ASX:SHG
Singular Health — Investor Presentation (December 2022)
21 slides from Singular Health's investor presentation, Dec 6, 2022
Slide 1: Delivering Personalised Healthcare through Technology
Delivering Personalised Healthcare through Technology Investor Presentation 6th December 2022 ASX: SHG
Slide 2: Disclaimer
Disclaimer This presentation (“Presentation”) has been prepared by Singular Health Group Ltd (“Singular Health” or Investment Risk “Company”). You must read and accept the conditions in this notice before considering the information set An investment in Singular Health shares is subject to known and
Slide 3: Company Snapshot
Company Snapshot Founded in 2017, Singular Health Group Ltd is an Australian-based medical technology company using emerging technologies to enable personalized healthcare with solutions such as fully-immersive 3D medical imaging, medical AI models, surgical design, and advanced manufacturing of pat
Slide 4: Company Snapshot
Company Snapshot Medical Software & Medical 3D Shares on Issue Printing Opportunity valued at 102,798,867 (As at 5th Dec 2022) $4.48B USD2 Market Cap* Chairman $14.9M* Howard Digby (As at 2 Dec 2022) Cash at Bank CEO $1.06M 3 Thomas Hanly Sector % of Shares Escrowed Medical Technology 36.5% & 3D Pri
Slide 5: Timeline since IPO (Part 1/2) Research & Development Phase
Timeline since IPO (Part 1/2) Research & Development Phase March 2021 June 2021 November 2021 Purchase of VR Virtual Surgical Software & Release of Innovative Medical File GeoVR JV to commercialise 3D/VR Investment in 25% shareholding of Medical Transfer Protocol (MFTP) mining software 3D Printing F
Slide 6: Timeline since IPO (Part 2/2) Commercialisation & Growth Phase
Timeline since IPO (Part 2/2) Commercialisation & Growth Phase October 2022 Received US FDA510(k) Diagnostic Clearance for 3Dicom MDTM August 2022 FDA510(k) Submission for 3Dicom MDTM to FDA November 2022 Appointment of US-Agent & US Sales Partner Receipt of $414K R&D Tax March 2022 September 2022 R
Slide 7: 3DICOM MD – Collaborative Diagnostic Review
3DICOM MDTM – Collaborative Diagnostic Review* Total Addressable Market in US Pricing 6,093 US Hospitals5 Monthly: USD$49.95/month 201,927 Dentists6 Annual: USD$399.95/year 34,920 Surgeons7 29,530 Radiologists8 Reimbursement4 Regulatory Strategy Existing CPT codes identified for 3D FDA510(k) cleared
Slide 8: 3DICOM Surgical – Medical Design Software
3DICOM Surgical – Medical Design Software* Total Addressable Market in US Pricing 29,590 Surgeons7 Monthly: USD$249.95/month 6,093 US Hospitals5 Annual: USD$1999.95/year 113 Hospitals with centralized 3D printing facilities (as at 2019)10 Reimbursement9 Regulatory Strategy Existing CPT codes for 3D
Slide 9: Scaling Singular Health – Enterprise Strategy
Scaling Singular Health– Enterprise Strategy Appointment of Global Joint Ventures in Macau, Partnerships Manager Singapore (SHG SEA), and GeoVR Cost-effective representation at international trade shows in USA and Europe Inbound enquiries for 3rd party integrations of AI models, hardware, and proces
Slide 10: Scaling Singular Health – Direct Sales Strategy
Scaling Singular Health – Direct Sales Strategy Global SaaS Management Platform 3rd Party Integrations & Add-Ons Affiliate & Partner Program Portal Singular Health has developed a proprietary, The customer dashboard is integrated with the 3Dicomviewer.com online portal is also used by online subscri
Slide 11: Localised Production with Global Scale
Localised Production with Global Scale UK & Europe Presence Kelyniam Local representation (US Agent) Macau JV CG1 Solutions (Sales Partner) Singapore JV Corporate HQ Software Development Global 3D Facility AAE Medical 3D Printing Facility © Singular Health 2022. All rights reserved. 11
Slide 12: Acquisition of Global3D – Medical 3D Printing
Acquisition of Global3D – Medical 3D Printing Global3D provides 3D printing services and design for both medical and non-medical applications. Global3D generated gross revenue of AUD$532,570 in FY2022 Well-established facility located in Bibra Lake, 20 km south of Perth, Western Australia Currently
Slide 13: Scaling Global3D – Patient Specific 3D Printing
Scaling Global3D – Patient Specific 3D Printing Australia’s Prosthetics & Orthotics Market size was estimated at USD$208.87 million in 2021 and is expected to grow at a compound annual growth rate Patient Specific Check of 5.45% to reach USD$287.30 million in 202111 Sockets for Prosthetics Patient S
Slide 14: Key Objectives in 2023
Key Objectives in 2023 Regulatory Commercial Product Roadmap Corporate • Obtain Health Canada (Q1 CY23), • Appointment of 10 sales partners • Enhance Global3D product offering • Identify and assess synergistic TGA (Australia) (Q2 CY23), and HSA and accelerate 3rd party with investment in post-proces
Slide 15: Investment Highlights
Investment Highlights Following a year of foundation building, including obtaining first diagnostic regulatory approval, undergoing audits for ISO standards, commissioning the 25% owned Melbourne 3D printing facility, and establishing global sales partnerships, Singular Health is well positioned for
Slide 16: Contact Us
Contact Us Thomas Hanly James Hill Dr Martina Mariano Corporate Investor Relations Sales / Partnerships thanly@singular.health jhill@singular.health mmariano@singular.health © Singular Health 2022. All rights reserved. 16
Slide 17: Appendix – Board and Senior Management
Appendix 1 – Board and Senior Management Howard Digby Thomas Hanly Non-Executive Chairman Managing Director & CEO With more than 25 years of experience Having a strong background in in technology companies and with funding, commercializing and broad ASX experience from multiple successfully exiting
Slide 18: Appendix - Scan to Surgery
Appendix 2 - Scan to SurgeryTM Virtual Surgical SCAN PACS 3D / VR Scan Review Medical AI Manufacturing Surgery Planning / Design Patient scan(s) taken using Patient’s scan(s) are stored Patient’s standard 2D scan(s) is Medical Computer Aided Advanced manufacturing Artificial intelligence models Surg
Slide 19: Appendix - 3DICOM Software Suite
Appendix 3 - 3DICOM Software Suite Product 3Dicom Patient 3Dicom MD 3Dicom Surgical 3Dicom R&D 3Dicom XR Lightweight, local 3D DICOM viewer Medical imaging software for Medical device design software for Medical image analysis Companion wireless app on Description for Windows and MacOS, plus iOS dia
Slide 20: Appendix - Regulatory Strategy
Appendix 4 - Regulatory Strategy Anticipated Approval Status Commercial Impact Timeline Major barrier to entry crossed with access gained to a significantly 3Dicom MD – US FDA510(k) Granted (October 2022) smaller competitive pool, higher prices compared to non-diagnostic Granted Q2 FY2022 patient ma
Slide 21: References
References 1 FDA510(k) Summary (K222470), accessed Nov 2022, https://www.accessdata.fda.gov/cdrh_docs/pdf22/K222470.pdf 2 Frost & Sullivan, accessed Nov 2022, https://ww2.frost.com/ 3 Singular Health Quarterly Activities / Appendix 4C Cash Flow Report (31/10/2022), accessed Nov 2022, https://investo
Singular Health Group — Investor Presentation (December 2022) on 6ix